NCT05081674View on ClinicalTrials.gov

Brazilian Lung Immunotherapy Study

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

July 30, 2023

Conditions
Lung Neoplasm
Interventions
DRUG

Alectinib

600mg 1OD

DRUG

Pembrolizumab

200mg every 21 days

DRUG

Nivolumab

6mg/kg every 4 weeks

DRUG

Erlotinib

150mg

Trial Locations (1)

04378-500

Hospital Municipal Vila Santa Catarina, São Paulo

All Listed Sponsors
collaborator

Ministry of Health, Brazil

OTHER_GOV

lead

Hospital Israelita Albert Einstein

OTHER

NCT05081674 - Brazilian Lung Immunotherapy Study | Biotech Hunter | Biotech Hunter